TriangleDurvalumab (NCT05061550)
Durvalumab trial for Non-small Cell Lung Cancer (NCT05061550). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for people aged 18–95 with newly diagnosed, removable stage IIA–IIIB non-small-cell lung cancer. Sensitizing EGFR mutations and ALK rearrangements are excluded; some arms require PD-L1 expression of at least 1%.
The idea: compare seven treatment regimens before and after surgery. Preoperative regimens combine chemotherapy with immune treatments, sometimes adding other targeted antibodies. Several use durvalumab, which blocks PD-L1 to support immune attack. Drug partners differ by arm.
This phase 2 study plans 630 patients. Tina Cascone leads at MD Anderson in Houston, with 17 recruiting US sites. AstraZeneca sponsors it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.